Biological Therapy in Treating Women With Breast Cancer That Has Spread to the Liver
Stopped early · Phase 1
Conditions studied: Breast Cancer, Metastatic Cancer
In brief
RATIONALE: Biological therapy using a gene-modified virus that can make interleukin-12 may help the body build an effective immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of a gene-modified virus that can make interleukin-12 in treating women with breast cancer that has spread to the liver.
Key facts
- Study ID
- NCT00301106
- Run by
- Max Sung
- People needed
- 2
- Starts
- 2005-10-01
- Expected to finish
- 2008-08-01
- Last updated by the study team
- 2017-02-02
Who can join
Age: 18 and older, up to 85. Sex: female. Healthy volunteers: not accepted.
Where it is running
- Mount Sinai Medical Center — New York, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.